Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.3611
Dollar change
-0.0049
Percentage change
-1.34
%
Index- P/E- EPS (ttm)-11.21 Insider Own1.33% Shs Outstand6.29M Perf Week-4.22%
Market Cap2.27M Forward P/E- EPS next Y-1.18 Insider Trans0.00% Shs Float6.20M Perf Month-19.76%
Income-13.48M PEG- EPS next Q-0.29 Inst Own3.22% Short Float3.03% Perf Quarter-64.94%
Sales0.07M P/S32.42 EPS this Y92.71% Inst Trans-13.38% Short Ratio0.12 Perf Half Y-78.63%
Book/sh-0.45 P/B- EPS next Y39.49% ROA-150.25% Short Interest0.19M Perf Year-90.13%
Cash/sh0.47 P/C0.76 EPS next 5Y- ROE-807.39% 52W Range0.32 - 4.38 Perf YTD-86.48%
Dividend Est.- P/FCF- EPS past 5Y32.13% ROI- 52W High-91.75% Beta0.36
Dividend TTM- Quick Ratio0.77 Sales past 5Y-20.00% Gross Margin82.43% 52W Low11.42% ATR (14)0.07
Dividend Ex-Date- Current Ratio0.77 EPS Y/Y TTM62.27% Oper. Margin-26555.41% RSI (14)37.78 Volatility10.19% 11.67%
Employees- Debt/Eq- Sales Y/Y TTM-80.98% Profit Margin-18217.57% Recom3.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q87.40% Payout- Rel Volume0.12 Prev Close0.37
Sales Surprise0.00% EPS Surprise66.67% Sales Q/Q-37.50% EarningsNov 12 AMC Avg Volume1.54M Price0.36
SMA20-4.59% SMA50-40.34% SMA200-75.35% Trades Volume185,233 Change-1.34%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $17
Apr-27-20Resumed ROTH Capital Buy $24
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Dec-05-24 04:05PM
Nov-14-24 04:15PM
Nov-13-24 12:22PM
Nov-12-24 06:00PM
04:45PM
09:15AM Loading…
Oct-24-24 09:15AM
Oct-23-24 09:15AM
Oct-09-24 09:15AM
Sep-25-24 09:15AM
Sep-04-24 09:15AM
Sep-03-24 09:15AM
Sep-02-24 09:55AM
Aug-14-24 05:35PM
04:05PM
Aug-07-24 09:15AM
12:00PM Loading…
Jul-25-24 12:00PM
Jun-26-24 09:15AM
Jun-06-24 12:00PM
Jun-04-24 08:00AM
Jun-03-24 08:00AM
May-15-24 05:01AM
May-14-24 04:05PM
May-08-24 09:15AM
May-02-24 04:30PM
Apr-30-24 02:37PM
07:47AM
07:31AM
07:00AM
Apr-01-24 09:15AM
Mar-20-24 10:05AM
08:53PM Loading…
Mar-19-24 08:53PM
04:05PM
Mar-13-24 04:05PM
Mar-07-24 09:15AM
Mar-06-24 09:15AM
Feb-20-24 09:15AM
Jan-30-24 09:15AM
Jan-09-24 09:07AM
Jan-08-24 09:15AM
Jan-02-24 09:15AM
Dec-22-23 09:15AM
Dec-20-23 10:52AM
10:51AM
Dec-18-23 09:00AM
Dec-12-23 04:05PM
Nov-30-23 09:15AM
Nov-29-23 12:34PM
Nov-28-23 05:15PM
Nov-14-23 10:46AM
Nov-13-23 04:05PM
Nov-07-23 09:15AM
Aug-10-23 06:42AM
Aug-09-23 04:05PM
Aug-03-23 09:15AM
Jul-13-23 12:00PM
May-16-23 11:42AM
May-12-23 05:52AM
May-11-23 04:05PM
May-04-23 09:15AM
May-03-23 09:15AM
Mar-08-23 10:45PM
Mar-07-23 09:15AM
06:10AM
Mar-06-23 04:05PM
Feb-27-23 09:15AM
Jan-30-23 09:15AM
Jan-05-23 09:15AM
Dec-15-22 09:15AM
Nov-09-22 04:05PM
Nov-07-22 10:33AM
Nov-03-22 09:15AM
Oct-26-22 09:15AM
Oct-24-22 09:15AM
Oct-13-22 09:15AM
Sep-21-22 09:15AM
Aug-10-22 04:05PM
Aug-03-22 09:15AM
Jun-30-22 12:46PM
09:15AM
Jun-22-22 07:04AM
Jun-14-22 09:23AM
May-11-22 04:05PM
May-04-22 09:15AM
Apr-19-22 09:15AM
Apr-15-22 08:33AM
Apr-12-22 07:00AM
Mar-28-22 04:05PM
Mar-22-22 07:00AM
Mar-09-22 07:00AM
Feb-07-22 07:00AM
Jan-06-22 07:00AM
Dec-23-21 07:00AM
Dec-20-21 02:00AM
Dec-07-21 05:25AM
Nov-10-21 04:05PM
Nov-05-21 09:41AM
Oct-29-21 07:00AM
Oct-04-21 09:00AM
Sep-08-21 07:00AM
Aug-11-21 04:05PM
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McBarron PaulSee RemarksDec 21 '23Buy3.311,8866,25233,378Dec 26 04:05 PM
Rombotis Spiro GeorgePresident and CEODec 21 '23Buy3.316,07020,12268,658Dec 26 04:05 PM